Vertex Pharmaceuticals Incorporated
VRTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. Valued at $131.08B, VRTX is a large-cap name in its sector. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Market Cap
$131.08B
Beta
0.28
P/E (TTM)
30.14
P/E (Fwd)
25.34
EPS (TTM)
$17.17
EPS (Fwd)
$20.42
ROE
23.5%
ROA
11.9%
Cash
$7.85B
Total Debt
$1.98B
Free CF
$2.63B
52W Change
23.2%
Annual Financials
Cash vs Debt
Where VRTX stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, VRTX finished 1.60% above its 150-day moving average ($477.60) and 2.10% above its 200-day moving average ($475.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRTX overbought or oversold?
At the October 14, 2026 close, VRTX's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $7.85B in cash comfortably exceeding the $1.98B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $2.63B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 23.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has grown from $8.93B (2022) to $12.00B (2025), reflecting a 34% increase over the period.
With a beta below 0.7, Vertex Pharmaceuticals Incorporated typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRTX.